Fenofibrate and human liver

Publisher Website
Google Scholar
Abstract
In rodents fenofibrate shares with other triglyceride-lowering agents the potential to increase the liver peroxisome population. It was therefore of interest to look for this effect in hyperlipoproteinemic patients receiving this drug. Light and electron microscopy of liver biopsies from a group of 10 patients treated with fenofibrate and from another group of 15 receiving diet only, show no morphological difference between both groups. In contrast with the rodent data the morphometric study reveals no significant changes in the number (fenofibrate group: 7.96 1010 cm−3; group receiving diet alone: 8.41 1010 peroxisomes/cm3 of liver tissue) or in the size (fenofibrate group: Diameter=0.53±0.07 μm — group receiving diet alone: 0.50±0.06) of peroxisomes. The difference between our results and those obtained consistently in rodents may be due to the relatively low dose in man and/or a species-dependant difference in enzyme content of liver peroxisomes, itself related to an apparent difference in the way in which lipids are handled.